Physician profile
Charles Roseman
NPI 1659668937
$1,629.78
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $197 · 2021: $262 · 2022: $346.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $258.00 | 2019 | |
| Shire North American Group INC | $224.35 | 2019 | |
| Allergan, INC. | $220.64 | 2019-2022 | |
| Abbvie INC. | $165.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $151.48 | 2019-2022 | |
| Alcon Vision LLC | $151.10 | 2021-2022 | |
| Ocular Therapeutix, INC. | $146.48 | 2020 | |
| Aerie Pharmaceuticals, INC. | $125.81 | 2019 | |
| Sight Sciences, INC. | $47.79 | 2019 | |
| Kala Pharmaceuticals, INC. | $47.32 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $35.68 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $31.22 | 2021 | |
| Genzyme Corporation | $24.24 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Roseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.